GLPwatch
[Natriuretic effect of exenatide: high efficacy and site of action].
Eksp Klin Farmakol · 2012
Last updated 2026-05-28In a study on rats, the diabetes drug exenatide caused a much stronger increase in urine production and sodium excretion than the common diuretic furosemide when given at the same dose. When both drugs were combined, their effects on urine and sodium output added up, suggesting they work in different parts of the kidney. The results hint that exenatide may block sodium reabsorption in an early section of the kidney’s filtering system.
AI summary of the abstract below.
| Journal | Eksp Klin Farmakol, 2012 |
|---|---|
| Citations | 1 |
| Relative citation ratio | 0.04 |
| NIH percentile | 4 |
| Molecules | exenatide |
| Conditions studied | Heart Failure |
Abstract
Exenatide injection to female Wistar rats induced an increase in diuresis, urinary sodium and mild potassium excretion. The maximum natriuretic effect of exenatide was 18500 times more pronounced compared to that of furosemide in equimolar dose. The natriuretic and diuretic effects after combined administration of maximum doses of exenatide and furosemide were additive, which was indicative of different mechanisms of their action on the nephron. Exenatide probably inhibits sodium reabsorption in renal proximal segment. The data obtained might be essential for assessment of the clinical use of exenatide to excrete extracellular fluid excess in cases of edemation and to maintain potassium balance.
Verbatim abstract via PubMed 22550855 ↗
Related research
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
- Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
- Exenatide and the treatment of patients with Parkinson's disease.
- Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.